Waste Benefits of a Reusable IoL Inserter in Cataract Surgery

Waste Benefits of a Reusable IoL Inserter in Cataract Surgery

Cataract surgery holds the title of the most frequently conducted surgical procedure globally. In the UK alone, Optegra – a provider of eye healthcare for the NHS – performs an average of 25 cataract surgeries per surgeon daily at each of their ~19 sites. This high...
Greener Maternity Care

Greener Maternity Care

Guidance on how to produce a carbon footprint of maternity services Maternity Care and Climate Change Maternity services are one of the NHS’s high-volume services, with over 673,000 births in the UK in 2022. Each of these will have been preceded by approximately 30...
Reducing the environmental impact of chronic kidney disease care

Reducing the environmental impact of chronic kidney disease care

Globally, it is recognised that health and care systems are undergoing transformative change to adapt to the needs of patients and communities, with increasing pressure to be financially, socially and environmentally sustainable. Appraising the sustainability of care...
In-Centre Haemodialysis at Newcastle upon Tyne Hospital

In-Centre Haemodialysis at Newcastle upon Tyne Hospital

In June 2019, Newcastle upon Tyne Hospitals NHS Foundation Trust (NUTH) became the first healthcare organisation in the world to declare a Climate Emergency, recognising that a climate emergency is also a health emergency, and committed to becoming a net-zero carbon...
Environmental Impact of PlGF-based testing for pre-eclampsia

Environmental Impact of PlGF-based testing for pre-eclampsia

The availability of quick, accurate blood tests that can help rule out pre-eclampsia (PE) is improving care for pregnant women and their unborn babies, reducing anxiety and saving the NHS money. The Oxford Academic Science Network, who have been championing the use of...
Care pathway for Monoclonal Antibody Therapy

Care pathway for Monoclonal Antibody Therapy

Care pathway for Monoclonal Antibody Therapy of Severe Eosinophilic Asthma The use of Monoclonal Antibody (Mab) therapy is relatively new and evolving, but promises to revolutionise the management of asthma. This study by AstraZeneca has demonstrated the value of...